BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cymbalta (Duloxetine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cymbalta (Duloxetine)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05110144-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT05110144)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2.\nStudy: Efficacy of Two Doses 
 of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05110144
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807866-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT06807866)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Duloxetine for Periope
 rative Pain in Hip Arthroplasty: A RCT\nEstimated primary completion: 1 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxeti
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6807866
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326163-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cymbalta (Duloxetine): Phase na readout est. (NCT07326163)
DESCRIPTION:Cymbalta (Duloxetine)\, phase na\, Fibromyalgia.\nStudy: The Ef
 fect of Peppermint Oil Aromatherapy on Pain\, Functional Capacity and Cost
  in Fibromyalgia Patients\nEstimated primary completion: 30 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07326163
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05814640-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cymbalta (Duloxetine): Phase 1/2 readout est. (NCT05814640)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 1/2.\nStudy: Sequenced Treatment 
 Alternatives to Relieve Adolescent Depression (STAR-AD)\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/duloxetine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05814640
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560673-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT04560673)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2.\nStudy: Duloxetine and Neurofe
 edback Training for the Treatment of Chemotherapy Induced Peripheral Neuro
 pathy\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04560673
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421427-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cymbalta (Duloxetine): Phase na readout est. (NCT07421427)
DESCRIPTION:Cymbalta (Duloxetine)\, phase na.\nStudy: Adding Amantadine or 
 Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome\nE
 stimated primary completion: 1 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07421427
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431606-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT07431606)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2.\nStudy: Duloxetine in Inflamma
 tory Bowel Diseases\nEstimated primary completion: 1 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/duloxetine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07431606
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400471-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Cymbalta (Duloxetine): Phase 1 readout est. (NCT07400471)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 1.\nStudy: The Effects of Preempt
 ive Multimodal Analgesic on Endodontic Pain Following Root Canal Therapy.\
 nEstimated primary completion: 30 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07400471
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914557-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT06914557)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2.\nStudy: Scrambler Therapy With
  Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemothera
 py-induced Peripheral Neuropathy.\nEstimated primary completion: 30 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06914557
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05851976-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT05851976)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Duloxetine for LBP\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/duloxetine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05851976
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976347-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT05976347)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Identifying and Treati
 ng Depression in the Orthopaedic Trauma Population\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dul
 oxetine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05976347
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785544-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cymbalta (Duloxetine): Phase na readout est. (NCT07785544)
DESCRIPTION:Cymbalta (Duloxetine)\, phase na\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Li
 poic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral N
 europathy\nEstimated primary completion: June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07785544
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860984-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Cymbalta (Duloxetine): Phase 3 readout est. (NCT06860984)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 3.\nStudy: Evaluating the Safety 
 and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde
  Cholangiopancreatography Pancreatitis\nEstimated primary completion: 20 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0686
 0984
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04970121-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT04970121)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2.\nStudy: Efficacy and Safety of
  Duloxetine in Chinese Solid Tumor Patients With Taxanes-induced Painful P
 eripheral Neuropathy\nEstimated primary completion: 1 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/duloxetine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04970121
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423716-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT06423716)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Effect of peRiopErativ
 e duLoxetIne Administration on Opioid Consumption Following Total kneE Art
 hroplasty (RELIFE)\nEstimated primary completion: 1 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/duloxetine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06423716
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06232473-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT06232473)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Patient Education and 
 Duloxetine\, Alone and in Combination\, for Patients With Multisystem Func
 tional Somatic Disorder\nEstimated primary completion: 1 November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06232473
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06245109-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT06245109)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Brain-Based and Clinic
 al Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis\nEstimated p
 rimary completion: 15 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/duloxetine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06245109
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06407401-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280418
DTEND;VALUE=DATE:20280419
SUMMARY:Cymbalta (Duloxetine): Phase 3 readout est. (NCT06407401)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 3.\nStudy: Improvement of Quality
  of Life Through Supportive Treatments for Hormone Therapy - Related Sympt
 oms in Patients With Early Breast Cancer\nEstimated primary completion: 18
  April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxeti
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6407401
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614322-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT06614322)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2\, Diabetic Peripheral Neuropath
 ic Pain.\nStudy: SPENDD: Quantitative Sensory Testing and Analgesic Respon
 se for Painful Peripheral Neuropathy.\nEstimated primary completion: 1 Jun
 e 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066143
 22
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05851898-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT05851898)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Serotonin-norepinephri
 ne Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fra
 ctures\nEstimated primary completion: December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05851898
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759336-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cymbalta (Duloxetine): Phase 4 readout est. (NCT07759336)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 4.\nStudy: Personalized Analgesia
  Through Central Nervous System Engagement to Unlock Performance\nEstimate
 d primary completion: December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/duloxetine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07759336
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731750-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Cymbalta (Duloxetine): Phase na readout est. (NCT07731750)
DESCRIPTION:Cymbalta (Duloxetine)\, phase na.\nStudy: Algorithm-informed De
 cision-making to Advance Pain Treatment\nEstimated primary completion: Feb
 ruary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxetin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 731750
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649291-7141@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT07649291)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2.\nStudy: Duloxetine and aeRobic
  Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE)
 \nEstimated primary completion: 1 September 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/duloxetine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07649291
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
